Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma

The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventua...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, H, Kircher, D A, Kim, K H, Grossmann, A H, VanBrocklin, M W, Holmen, S L, Robinson, J P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501768/
https://www.ncbi.nlm.nih.gov/pubmed/28263969
http://dx.doi.org/10.1038/onc.2016.526

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5501768/
https://www.ncbi.nlm.nih.gov/pubmed/28263969
http://dx.doi.org/10.1038/onc.2016.526

Ejemplares similares